Safety
deaths, nasopharyngitis, headache
ADVERSE EVENT, NASOPHARYNGITIS, PROSTATE CANCER
Adverse events (AEs) were experienced by 3/8 (38%) participants with GSK3772847 and 7/9 (78%) participants with placebo, most commonly nasopharyngitis (GSK3772847, n = 1; placebo, n = 2) and headache (GSK3772847, n = 1; placebo, n = 2). No drug-related AEs or serious AEs were reported in the GSK3772847 arm. In the placebo arm, one drug-related AE was reported, and one participant experienced a non-fatal serious AE (prostate cancer). No deaths were reported. There were no clinically significant changes from baseline in electrocardiogram results or vital signs. One participant in each arm experienced an increase in QTcF values (>30 to ≤60 msec) post baseline.